We develop first-in-class stapled peptide therapeutics for the treatment of Severe Viral Diseases. RSV is the most common pathogen associated with respiratory infections such as bronchiolitis, croup and pneumonia. The total direct cost for health care system is about 5bn/year. Currently there are no good therapeutics on the market. ViRelieve develops first-in-class peptides with great added value compare to small molecules and antibodies. Our broad vision is the development of a technology platform targeting several viruses in the same family (Parainfluenza, MetaPneumovirus, Ebola, Zika and Nipah).
